How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?
Authors:
Open Access
- 22 February 2017
- journal article
- editorial
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (4) , 591-593
Abstract
Making the right clinical decisions for rare diseases with the right toolsKeywords
This publication has 10 references indexed in Scilit:
- Documentation of off-label use of biologics in Rheumatoid ArthritisAnnals of the Rheumatic Diseases, 2013
- Adaptive Licensing: Taking the Next Step in the Evolution of Drug ApprovalClinical Pharmacology & Therapeutics, 2012
- Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registryRheumatology, 2011
- DANBIO--powerful research database and electronic patient recordRheumatology, 2010
- European biologicals registers: methodology, selected results and perspectivesAnnals of the Rheumatic Diseases, 2009
- Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvementAnnals of the Rheumatic Diseases, 2005
- When are observational studies as credible as randomised trials?The Lancet, 2004
- From best evidence to best practice: effective implementation of change in patients' careThe Lancet, 2003
- A Comparison of Observational Studies and Randomized, Controlled TrialsNew England Journal of Medicine, 2000
- Problems in the “Evidence” of “Evidence-Based Medicine”The American Journal of Medicine, 1997